

ML# 341090

RECEIVED  
OPPT CBIC

January 23, 2012

2012 JAN 24 AM 10:40

Contains TSCA Confidential Business  
Information within brackets {}  
**Sanitized Copy**

TSCA Confidential Business Information Center (7407M)  
EPA East – Room 6428 Attn: Section 8(e)  
U.S. Environmental Protection Agency  
1200 Pennsylvania Avenue, NW  
Washington, DC 20460-0001

8EHQ-0112-18537A

88120000080s



**Subject:** Notice in Accordance with TSCA Section 8(e): Results of a Toxicity Study: [One Week Oral Toxicity Study of \_\_\_\_\_ in Dogs]

Dear Sir/Madam,

{\_\_\_\_}, submits this letter under section 8(e) of the Toxic Substances Control Act (TSCA) to inform the U.S. Environmental Protection Agency (EPA) of the results of toxicity testing with an early stage experimental pesticide being screened for potential registration and development in the United States.

The subject study was conducted with {\_\_\_\_}, no CAS No. available. Details of the study are attached.

{\_\_\_\_} understands that reporting of results from this study under TSCA 8(e) is in accordance with EPA's policy. {\_\_\_\_} has not made a determination at this time that any substantial risk of injury to human health or the environment is presented by the findings within the subject study.

Please note that a confidential version of this letter is enclosed, treating the chemical identity and company identity as Confidential Business Information.

A Confidentiality Substantiation Questionnaire is being submitted for the substance.

If you have any questions with regard to this submission, please contact me at {\_\_\_\_\_}.

Sincerely,

{\_\_\_\_\_}



Attachments

**Company Sanitized**

RECEIVED  
OPPT CBIC  
2012 JAN 24 AM 10:40

TEST SUBSTANCE: \_\_\_\_\_

REFERENCE No.: IET 11-0032

TITLE: One Week Oral Toxicity Study of \_\_\_\_\_ in Dogs

[CONTENTS]

Dogs receiving \_\_\_\_\_ via the diet showed clonic convulsion, tremor, staggering gait, falling and salivation. Moreover, No-observed-adverse-effect level (NOAEL) was lower than 4250 ppm (133 mg/kg/day for male and 129 mg/kg/day for female).

We judged these results met the criteria for reporting.

[COMMENTS]

METHOD:

Test substance: \_\_\_\_\_ (Purity; 99.6 %, Lot No.: 276-100317-1)

Animals: Male and Female, Beagle, 5 months old at administration

Body weight: 8.2.9.3 kg (Male), 8.4.8.9 kg (Female)

Treatment periods: two (First administration) and eight (Second administration) days\*

Route of administration: Oral (Dietary)

Dose level : 0, 17500, 35000 ppm (First administration)

0, 4250, 8500 ppm (Second administration)\*

1 animal /dose /sex

Examination items: clinical signs, body weights, body weight gains, food consumption, hematology, blood biochemistry

Other findings: Vomiting, Decreased spontaneous motor activity, Lateral position, Crouching position

\*: The First administration (17500 and 35000 ppm) was interrupted because serious neurotoxic signs (i.e. clonic convulsion) and remarkable loss of food consumption were observed during 2 days of the First administration. Then, following a 3-day withdrawal period, the Second administration (4250 and 8500 ppm) for eight days was performed.

(Completed)